Cardiovascular Effects of TKIs in the Treatment of CML
Dr Christopher Plummer is a consultant cardiologist at the Freeman Hospital in Newcastle upon Tyne in the UK. He has a major clinical and research interest in cardiovascular effects of cancer treatments. He has co-written cardio-oncology guidance in 3 areas and given advice on more than 50 clinical trials. He is a founder member of the British Cardio-Oncology Society (BC-OS.org) whose mission is to promote research, best clinical practice and a wider understanding of the effects of cancer treatment on the cardiovascular system. His other interests include implantable cardiac rhythm device management, medical education and the use of information technology in medicine.
Title: Second Generation TKI’s in the Management of CML (Dr. Fausto Castagnetti).
Dr Fausto Castagnetti shares his expertise in chronic myeloid leukemia (CML) management. As an expert in CML he has authored or co-authored more than 70 publications and 270 abstracts. He is an active member of the Italian Hematologic Diseases group and the Chronic Myeloid Leukemia Working Party, a research group coordinating more than 90 centers in Italy. He is also a member of the European Investigators on CML and has participated in the European project EUTOS (European Treatment and Outcome Study) to improve understanding of CML, promote best practice, and enhance treatment outcomes, through 4 key projects: CML registry, Molecular monitoring, Path to cure and Spread of Excellence.
Title: Treatment of Chronic Myeloid Leukemia with second generation TKIs (Dr. Jeroen Janssen)
Dr. Jeroen Janssen, Consultant Haematologist based in Amsterdam, the Netherlands, is the principal investigator for a range of Phase II and III CML clinical trials including the ongoing NordDutch CML 009, RAND, EURO-SKI and NiFo-studies. At the Vrije Universiteit medical center in Amsterdam, he supervises the largest CML treatment center in the Netherlands. He is a co-director of the stem cell transplant program and is the local JACIE laboratory medical director. Jeroen Janssen has undertaken various research projects in CML including “Identification of Leukemia Stem Cell Specific Targets in CML” and “Compliance Improvement of Tyrosine Kinase Inhibitor Therapy in CML”. He has published extensively (77 publications) and peer-reviews articles submitted to several major journals in haemato-oncology.